Enfortumab Vedotin-ejfv
CAS: 1346452-25-2
Description:
Enfortumab vedotin-ejfv is an antibody-drug conjugate (ADC) used to treat cancers that express Nectin-4. It combines an anti-Nectin-4 monoclonal antibody with the cytotoxic drug monomethyl auristatin E (MMAE), which disrupts microtubules and kills cancer cells. The antibody specifically targets Nectin-4 on tumor cells, delivering MMAE directly to the cancer site. It is mainly used to treat locally advanced or metastatic urothelial carcinoma (bladder cancer).
Key Features:
- Nectin-4 Targeting: The antibody binds specifically to Nectin-4, a protein highly expressed on cancer cells, enabling targeted drug delivery.
- Cytotoxic Agent (MMAE): MMAE inhibits microtubule function, leading to cancer cell death.
- Linker Technology: The stable linker ensures MMAE reaches the tumor cells directly for effective treatment.
Applications:
- Cancer Treatment: Targets and destroys Nectin-4-positive cancer cells, especially in urothelial carcinoma (bladder cancer).
- Targeted Therapy: Delivers MMAE directly to the tumor, reducing side effects and sparing healthy tissue.
- Monoclonal Antibody Therapy: Provides a targeted, effective treatment for patients with Nectin-4-expressing tumors.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.